Submission for OMB Review; 30-Day Comment Request; Health Information National Trends Survey (HINTS) (NCI), 8886-8887 [2015-03382]
Download as PDF
8886
Federal Register / Vol. 80, No. 33 / Thursday, February 19, 2015 / Notices
• A statement of either the quantity or
volume of the repackaged drug product,
whichever is appropriate.
• The date the drug product was
repackaged.
• The beyond-use-date of the
repackaged drug product.
• Storage and handling instructions
for the repackaged drug product.
• The National Drug Code (NDC)
number of the repackaged drug product,
if available.1
• The statement ‘‘Not for resale,’’ and,
if the drug is distributed by an
outsourcing facility other than pursuant
to a prescription for an individual
identified patient, the statement ‘‘Office
Use Only.’’
• If included on the label of the FDAapproved drug product from which the
drug product is being repackaged, a list
of the active and inactive ingredients,
unless such information is included on
the label for the container from which
the individual units are removed, as
described in this document.
In addition, a condition in the draft
guidance is that the label on the
container from which the individual
units are removed for administration
(secondary packaging, e.g., the bag, box,
or other package in which the
repackaged products are distributed)
includes the active and inactive
considered a collection of information
under the PRA because the information
is ‘‘originally supplied by the Federal
Government to the recipient for the
purpose of disclosure to the public’’ (5
CFR 1320.3(c)(2)).
We also estimate that annually a total
of approximately 10 outsourcing
facilities (‘‘Number of Respondents’’ in
table 1, row 2) will each produce a copy
of prescribing information as set forth in
section III.A.11 of the draft guidance for
approximately 10 repackaged drug
products (‘‘Frequency per Disclosure’’
in table 1, row 1) for a total of 100
disclosures (‘‘total disclosures’’ in table
1, row 2). We also estimate that
providing prescribing information
labeling will take approximately 1 hour
for each repackaged drug product
(‘‘Hours per Disclosure’’ in table 1, row
2). The provision to add https://
www.fda.gov/medwatch and 1–800–
FDA–1088 is not included in this
burden estimate because it is not
considered a collection of information
under the PRA because the information
is ‘‘originally supplied by the Federal
Government to the recipient for the
purpose of disclosure to the public’’ (5
CFR 1320.3(c)(2)).
The total estimated third-party
disclosure burden resulting from the
draft guidance is as follows:
ingredients, if the immediate product
label is too small to include this
information, and directions for use,
including, as appropriate, dosage and
administration, and the following
information to facilitate adverse event
reporting: https://www.fda.gov/
medwatch and 1–800–FDA–1088.
Another condition in the draft
guidance is that each repackaged drug
product is accompanied by a copy of the
prescribing information that
accompanied the original drug product
that was repackaged.
We estimate that annually a total of
approximately 10 outsourcing facilities
(‘‘Number of Respondents’’ in table 1,
row 1) will each design, test, and
produce approximately 10 different
labels (‘‘Frequency per Disclosure’’ in
table 1, row 1) for a total of 100 labels
that include the information set forth in
section III.A.11 of the draft guidance
(including directions for use) (‘‘Total
Disclosures’’ in table 1, row 1). We also
estimate that designing, testing, and
producing each label will take
approximately 0.5 hours for each
repackaged drug product (‘‘Hours per
Disclosure’’ in table 1, row 1). The
provision to add the statement https://
www.fda.gov/medwatch and 1–800–
FDA–1088 is not included in this
burden estimate because it is not
TABLE 1—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN
Number of
respondents
Repackaging by outsourcing facilities
Frequency per
disclosure
Total
disclosures
Hours per
disclosure
Total hours
Designing, testing, and producing each label on immediate
containers, packages and/or outer containers .................
Prescribing information labeling produced for each repackaged drug product ............................................................
10
10
100
.5
50
10
10
100
1
100
Total ..............................................................................
........................
........................
........................
........................
150
emcdonald on DSK67QTVN1PROD with NOTICES
There are no capital costs or operating and maintenance costs associated with this collection of information.
*(30 minutes)
The draft guidance also references
registration, product reporting, and
CGMP requirements for outsourcing
facilities. In the Federal Register of
December 4, 2013 (78 FR 72899), FDA
estimated the burden resulting from
outsourcing facility registration. In the
Federal Register of December 4, 2013
(78 FR 72897), FDA estimated the
burden resulting from outsourcing
facility interim product reporting. In the
Federal Register of July 2, 2014 (79 FR
37743), FDA estimated the burden
resulting from outsourcing facility
compliance with CGMP requirements.
V. Electronic Access
Persons with access to the Internet
can obtain the document at either https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
Dated: February 11, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–03417 Filed 2–18–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Health Information
National Trends Survey (HINTS) (NCI)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH), has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
SUMMARY:
1 The NDC number of the original approved drug
product should not be placed on the repackaged
drug product.
VerDate Sep<11>2014
16:58 Feb 18, 2015
Jkt 235001
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
E:\FR\FM\19FEN1.SGM
19FEN1
8887
Federal Register / Vol. 80, No. 33 / Thursday, February 19, 2015 / Notices
listed below. This proposed information
collection was previously published in
the Federal Register on December 4,
2014 (Vol. 79, No. 233, pages 72003—
4) and allowed 60 days for public
comment. A total of five public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Cancer Institute (NCI),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Direct Comments To OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
public’s knowledge of medical devices,
communications related to product
recalls, nutritional supplement labeling,
and topics to inform FDA’s regulatory
authority over tobacco, such as risk
perceptions about new tobacco
products, product pack color gradations,
perceptions of product harm, and
tobacco product claims and labels. This
HINTS survey will couple knowledgerelated questions with inquiries into the
communication channels through which
understanding is being obtained, and
assessment of FDA-regulated material.
This survey will extend the information
collected and priorities from HINTS
which have been to provide a
comprehensive assessment of the
American public’s current access to, and
use of, information about cancer across
the cancer care continuum from cancer
prevention, early detection, diagnosis,
treatment, and survivorship.
OMB approval is requested for 1 year.
There are no costs to respondents other
than their time. The total estimated
annualized burden hours are 2,159.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments or request more
information on the proposed project
contact: Bradford W. Hesse, Ph.D.,
Health Communication and Informatics
Research Branch, 9609 Medical Center
Drive, MSC 9761, Room 3E610,
Rockville, MD 20850 or call non-toll
free number 240–276–6721 or Email
your request, including your address, to
hesseb@mail.nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
Proposed Collection: Health
Information National Trends Survey
(HINTS) 0925–0538, Reinstatement with
Change, National Cancer Institute (NCI),
National Institutes of Health (NIH).
Need and Use of Information
Collection: This partnership between
NCI and FDA will include assessing the
DATES:
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Number of
respondents
Number of
responses
per respondent
Average
burden per
response
(in hours)
Total annual
burden hour
Individuals ........................................................................................................
4,318
1
30/60
2,159
Dated: February 9, 2015.
Karla Bailey,
NCI Project Clearance Liaison, National
Institutes of Health.
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2015–03382 Filed 2–18–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
emcdonald on DSK67QTVN1PROD with NOTICES
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Sep<11>2014
16:58 Feb 18, 2015
Jkt 235001
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Short-term Educational Experiences in
Hematology.
Date: March 11, 2015.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda; One
Bethesda Metro Center; 7400 Wisconsin
Avenue; Bethesda, MD 20814.
Contact Person: Melissa E Nagelin, Ph.D.;
Scientific Review Officer; Office of Scientific
Review/DERA; National Heart, Lung, and
Blood Institute; 6701 Rockledge Drive; Room
7202; Bethesda, MD 20892; 301–435–0297;
nagelinmh2@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
International Strategic Timing of
Antiretroviral Therapy.
Date: March 13, 2015.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health; 6705
Rockledge Drive, Room 7188; Bethesda, MD
20817; (Telephone Conference Call).
Contact Person: Chang Sook Kim, Ph.D.;
Scientific Review Officer; Office of Scientific
Review/DERA; National Heart, Lung, and
Blood Institute; 6701 Rockledge Drive; Room
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
7188; Bethesda, MD 20892–7924; 301–435–
0287; carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS).
Dated: February 12, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–03344 Filed 2–18–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\19FEN1.SGM
19FEN1
Agencies
[Federal Register Volume 80, Number 33 (Thursday, February 19, 2015)]
[Notices]
[Pages 8886-8887]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-03382]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day Comment Request; Health
Information National Trends Survey (HINTS) (NCI)
SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Institutes of Health (NIH), has
submitted to the Office of Management and Budget (OMB) a request for
review and approval of the information collection
[[Page 8887]]
listed below. This proposed information collection was previously
published in the Federal Register on December 4, 2014 (Vol. 79, No.
233, pages 72003--4) and allowed 60 days for public comment. A total of
five public comments were received. The purpose of this notice is to
allow an additional 30 days for public comment. The National Cancer
Institute (NCI), National Institutes of Health, may not conduct or
sponsor, and the respondent is not required to respond to, an
information collection that has been extended, revised, or implemented
on or after October 1, 1995, unless it displays a currently valid OMB
control number.
Direct Comments To OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974,
Attention: NIH Desk Officer.
DATES: Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30-days
of the date of this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments or request more information on the
proposed project contact: Bradford W. Hesse, Ph.D., Health
Communication and Informatics Research Branch, 9609 Medical Center
Drive, MSC 9761, Room 3E610, Rockville, MD 20850 or call non-toll free
number 240-276-6721 or Email your request, including your address, to
hesseb@mail.nih.gov. Formal requests for additional plans and
instruments must be requested in writing.
Proposed Collection: Health Information National Trends Survey
(HINTS) 0925-0538, Reinstatement with Change, National Cancer Institute
(NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: This partnership between
NCI and FDA will include assessing the public's knowledge of medical
devices, communications related to product recalls, nutritional
supplement labeling, and topics to inform FDA's regulatory authority
over tobacco, such as risk perceptions about new tobacco products,
product pack color gradations, perceptions of product harm, and tobacco
product claims and labels. This HINTS survey will couple knowledge-
related questions with inquiries into the communication channels
through which understanding is being obtained, and assessment of FDA-
regulated material. This survey will extend the information collected
and priorities from HINTS which have been to provide a comprehensive
assessment of the American public's current access to, and use of,
information about cancer across the cancer care continuum from cancer
prevention, early detection, diagnosis, treatment, and survivorship.
OMB approval is requested for 1 year. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 2,159.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Number of responses per per response Total annual
respondents respondent (in hours) burden hour
----------------------------------------------------------------------------------------------------------------
Individuals................................. 4,318 1 30/60 2,159
----------------------------------------------------------------------------------------------------------------
Dated: February 9, 2015.
Karla Bailey,
NCI Project Clearance Liaison, National Institutes of Health.
[FR Doc. 2015-03382 Filed 2-18-15; 8:45 am]
BILLING CODE 4140-01-P